News

Gene therapy back on track
Enlarge image

BusinessNetherlands

Gene therapy back on track

23.07.2012 - A ray of hope for Dutch gene therapy specialist uniQure B.V.: EMA's CHMP
recommended approval of its product Glybera to treat lipoprotein lipase (LPL) deficiency in patients with severe or multiple pancreatitis attacks.

EMA said Glybera (alipogene tiparvovec) is the first gene therapy drug to receive a positive CHMP recommendation. The news is a relief for Amsterdam-based uniQure, after having received three negative opinions before. CHMP said it reversed its prior negative opinions following a draft positive opinion in June from the Committee for Advanced Therapies (CAT),which conducted additional analyses of the data for the adeno-associated virus (AAV) vector encoding LPL gene. CHMP said Glybera should be approved under EMA's exceptional circumstances clause, and that the company be required to establish a patient registry to monitor outcomes. uniQure expects a final decision from the European Commission within three months.

UniQure's predecessor, Amsterdam Molecular Therapeutics Holding N.V., first applied for European approval of the gene therapy in December 2009 for all patients with LPL deficiency. CHMP subsequently issued three negative opinions for Glybera, the most recent of which came in April following arequest by the EC to consider the product in a restricted patient population with severe or multiple pancreatitis attacks. Amsterdam Molecular dissolved into uniQure this February.

LPL disease is a very rare, inherited disease which affects 1-2 people per million. Patients with the disease are unable to handle fat particles in their blood plasma, which leads to recurring severe abdominal pain andpancreatitis. "After today's positive recommendation, Glybera is poised tobecome the first in a class of gene therapy products approved in Europe to treat orphan diseases, rare conditions with a very high unmet medical need", Jörn Aldag, CEO of uniQure, said.

http://www.european-biotechnology-news.com/news/news/2012-03/gene-therapy-back-on-track.html

RegulationItalyGermanyNetherlandsEU

28.11.2014 The first gene therapy for a rare genetic condition — UniQure's Glybera — is on its way to the European market. But there is a hefty price tag: Chiesi, responsible for the marketing of the orphan drug, is asking for a record price of €1.1m per patient.

New reportEU

25.11.2014 The European biotech IPO slump has finally come to an end. A brand new industry report shows that compared to previous years, the number of biotech IPOs more than doubled in 2014, with London and Paris exchanges leading the pack.

M&AIreland

19.11.2014 It’s not every day that a company is pushed into the top ten of its sector, but that day has come for Actavis. Christmas came early for the new pharma giant after completing a US$66bn (€53bn) takeover battle for the Botox manufacturer Allergan.

Drug DevelopmentGermany

18.11.2014 Merck KGaA and US rival Pfizer have signed a immuno-oncology alliance worth billions: Merck will share the development and commercialisation of its cancer antibody with its US partner – for €2.3bn.

FinanceFrance

14.11.2014 Cosily coinciding with World Diabetes Day on 14th November, French biopharma Les Laboratories Servier has struck a US$1bn deal with US pharma Intarcia Therapeutics for the exclusive rights to Intarcia’s unprecedented therapy for type 2 diabetes.

AwardsFranceGermanySweden

12.11.2014 Glitz and glamour are not words often used to describe science and mathematics. But once a year, celebrities from the science and showbiz world come together at the Breakthough Prizes, a glitzy television bash that honours scientists for their achievements. French life scientist Emmanuelle Charpentier was among this year’s winners.

ResearchEU

10.11.2014 EFPIA’s specialised group Vaccines Europe and the Innovative Medicines Initiative (IMI) have launched a €280m Call for proposals aimed to address the Ebola crisis.

Trade fairGermanyEU

07.11.2014 3,200 participants from 54 countries attended the 20th issue of BIO-Europe. The overall mood of the European biotech sector was modestly optimistic.

AcquisitionGermanyUKSweden

05.11.2014 German Definiens AG has a new owner: Astrazeneca’s biologics R&D arm Medimmune has taken over all the shares of the imaging specialist for US$150m.

AcquisitionSwedenDenmarkUK

04.11.2014 Galecto Biotech has entered an agreement with Bristol-Myers Squibb for the acquisition of the company and its lead drug, providing the Swedish company with the potential of reaching over US$400m.

Events

All Events

Current issue

All issues

Product of the week

Products